Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance oral vinorelbine versus erlotinib after carboplatin + vinorelbine induction in elderly metastatic non-small cell lung cancer
ACTRN12612000473864Phase 2Not yet recruiting
- Sponsor
- SouthernBiotech
- Start
- Jun 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine, carboplatin and erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SouthernBiotech. Primary endpoints: Quality of life and Progression-free survival. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
vinorelbinecarboplatinerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12612000473864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000473864.